Pursuant to approval of the members of the company through Postal Ballot, Caplin Point Laboratories has informed that the Board of Directors of the company at their meeting held today, has considered and approved the Business Transfer Agreement to be entered into with its Wholly Owned Subsidiary Company, Caplin Steriles for transfer of business undertaking of the company (Regulated Markets Injectable Business, including US FDA approved Injectable Plant and DSIR recognized R&D Units CP4 and CP5) by way of slump sale on a going concern basis. The Board of Directors Meeting commenced at 12.00 PM and concluded at 12.45 PM.
The above information is a part of company’s filings submitted to BSE.
